Achmea Investment Management B.V. Has $74.22 Million Stock Position in Johnson & Johnson $JNJ

Achmea Investment Management B.V. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 400,291 shares of the company’s stock after purchasing an additional 71,471 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of Achmea Investment Management B.V.’s investment portfolio, making the stock its 15th largest holding. Achmea Investment Management B.V.’s holdings in Johnson & Johnson were worth $74,222,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank increased its position in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. boosted its position in Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after buying an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. grew its stake in Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after buying an additional 6,584 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves ICOTYDE (icotrokinra), J&J’s once‑daily oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis — a first‑in‑class oral alternative to leading injectable IL‑23 therapies that could expand patient access and drive new prescription revenue. US FDA approves J&J’s oral psoriasis pill
• Positive Sentiment: HSBC raised its JNJ price target to $280 (from $265) and reiterated a Buy, citing healthcare strength and likely improved near‑term fundamentals — this adds analyst support and gives upside cushion relative to current levels. HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
• Neutral Sentiment: Analyst commentary and comparisons (e.g., J&J vs Merck) highlight relative strengths/risks across pipelines and cash flows — useful context but not an immediate catalyst. J&J or Merck? Key Factors Investors Must Weigh Right Now
• Neutral Sentiment: Market watchlists and “stocks to watch” mentions raise visibility but don’t change fundamentals immediately. 4 stocks to watch on Wednesday: T, M, MU, JNJ
• Negative Sentiment: Shares recently pulled back (reports of a slide and lower intraday volume) indicating short‑term profit‑taking despite the positive drug news and analyst upgrade; that pressure likely explains the stock trading down today. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $237.15 on Thursday. The stock has a market cap of $571.21 billion, a P/E ratio of 21.46, a price-to-earnings-growth ratio of 2.35 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The stock’s 50-day moving average price is $233.95 and its two-hundred day moving average price is $207.76. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Leerink Partners lifted their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, HSBC increased their target price on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $236.17.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.